Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 1.00 |
| ▸ | DPP7 | Q9UHL4 | 13/20 | 1.00 |
| ▸ | DPP8 | Q6V1X1 | 12/20 | 1.00 |
| ▸ | DPP9 | Q86TI2 | 12/20 | 1.00 |
| ▸ | FAP | Q12884 | 11/20 | 1.00 |
| ▸ | PREP | P48147 | 3/20 | 0.60 |
| ▸ | PITRM1 | Q5JRX3 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3092661 | 1.00 | DPP4 (1.00) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL7938765 | 1.00 | DPP4 (1.00) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL12340775 | 0.92 | DPP4 (0.85) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL7932223 | 0.87 | DPP4 (0.78) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL8228598 | 0.86 | DPP4 (1.00) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL12340772 | 0.86 | DPP4 (1.00) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL7943687 | 0.86 | DPP4 (0.78) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL12340760 | 0.85 | DPP4 (1.00) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL15334549 | 0.84 | DPP4 (1.00) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL12657353 | 0.84 | DPP4 (1.00) | DPP4DPP7DPP8DPP9FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130137629-A1 | COMBINATION TREATMENT FOR METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2013-05-30 | — | — | US | disclosed |
| US-20100227809-A1 | COMBINATION TREATMENT FOR METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2010-09-09 | — | — | US | disclosed |
| EP-2056673-A2 | COMBINATION TREATMENT FOR METABOLIC DISORDERS | Wellstat Therapeutics Corporation (US) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008022267-A2 | COMBINATION TREATMENT FOR METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227809-A1 | COMBINATION TREATMENT FOR METABOLIC DISORDERS | DPP8, GPR119, GLP1R | DPP4 5/4885DPP7 4/4885DPP8 1/4885 |
| US-20130137629-A1 | COMBINATION TREATMENT FOR METABOLIC DISORDERS | DPP8, GLP1R, GPR119 | DPP4 5/4885DPP7 7/4885DPP8 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.